Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated mucin-1 (TA-MUC1) antibody, from Glycotope for $132.5m. The gatipotuzumab ...

TOKYO & BASKING RIDGE, N.J., January 13, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property ...

After a string of new approvals, Daiichi Sankyo is boosting sales projection for AstraZeneca-partnered star cancer drug Enhertu. Daiichi now expects Enhertu could reach sales of 195.2 billion ...

Daiichi Sankyo is poised to play its part in revolutionizing cancer treatments with its portfolio of antibody-drug conjugates, that target $15 billion-plus annual revenue opportunities.

Agreement builds on and complements Daiichi Sankyo and Merck’s shared commitment to develop novel medicines for patients with cancer Daiichi Sankyo and Merck to co-develop and co-commercialize ...

Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market ...

As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize treatment standards. Daiichi Sankyo, a pharmaceutical group boasting over ...

Daiichi Sankyo is a Japanese pharmaceutical company known for its flagship products Lixiana and Enhertu. Enhertu is becoming a popular treatment for breast cancer, based on technology that is ...

Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sunao Manabe, DVM, PhD, will continue to serve as representative director and ...

(RTTNews) - Daiichi Sankyo (DSKYF.PK) and Merck & Co Inc. (MRK) said that they have reached a global development and commercialization agreement worth up to $22 billion for three of Daiichi Sankyo ...

TOKYO, Oct 19 (Reuters) - Drugmaker Merck (MRK.N), opens new tab will pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs, they said, in a deal that could be ...